Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIT: Virus-specific T-cells for CMV and Adenovirus post-HSCT
NCT02702427Phase 2Withdrawn
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Aug 2016
- Primary completion
- Apr 2019
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of short-term expanded virus-specific T-cells (St. Anna Kinderkrebsforschung) in cytomegalovirus infection (CMV) and adenovirus infection, sponsored by St. Anna Children's Cancer Research Institute. Primary endpoints: Incidence of Grade III-IV Allergic reaction, Anaphylaxis, Cytokine release syndrome or Serum sickness at 48 hours, Incidence of de novo acute GvHD > Grade II or increase of pre-existing GvHD at 8 weeks and 1 more. Planned start Aug 2016; status: withdrawn.
02
Drugs
short-term expanded virus-specific T-cells (St. Anna Kinderkrebsforschung)
03
Conditions
cytomegalovirus infection (CMV)adenovirus infection
Beyond the preview
Go deeper on NCT02702427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702427.